Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TAK-536 Pediatric Formulation in Healthy Adults
NCT03434977Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach the Maximum Plasma Concentration and 8 more. Started Feb 2018; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03434977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03434977.